

AVI BIOPHARMA INC
Form 8-K
November 05, 2002

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 5, 2002**

AVI BioPharma, Inc.

(Exact name of registrant as specified in its charter)

Oregon

*(State or other jurisdiction of
incorporation or organization)*

0-22613

(Commission File Number)

93-0797222

(IRS Employer Identification Number)

**One S.W. Columbia, Suite 1105
Portland, OR 97258**

(Address of principal executive offices)

(503) 227-0554

Registrant's telephone number, including area code

Item 5. Other Events.

AVI BioPharma, Inc. (the "Company") issued a press release on November 5, 2002, before the opening of trading in its Common Stock on the Nasdaq National Market System, a copy of which is attached as Exhibit 99.

The Press Release announces Third Quarter Financial Results and updates the Company's product research and clinical trials.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

None

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on November 5, 2002.

AVI BioPharma, Inc.

By: /s/ ALAN P.TIMMINS

Alan P. Timmins
President and Chief Operating Officer
(Principal Operating Officer)